Insights into the Future of Healthcare

How Does 340B Impact the Economics of a Drug? A 340B 101 with Sabrina Aery

Sabrina Aery, a 340B expert with more than 30 years of experience across hospitals, health plans, pharmaceutical manufacturers, and consulting, joins Perspectives to provide a 340B 101. She discusses the foundations of the program, how it works in practice, and how the program layers into the broader pharmaceutical pricing system. The episode concludes by discussing how the 340B program can impact the economics of a prescription drug and what biotech investors and executives can consider when evaluating potential 340B exposure. Topics discussed include: Who qualifies as a 340B covered entity and which patients and drugs may fall within the program, How 340B ceiling prices are determined, How 340B can affect gross-to-net, net price, and revenue forecasting, Three things biotech executives and investors can examine to assess a product’s potential 340B exposure, and Whether you work in biotech or simply want to better understand the U.S. drug pricing system, this episode explains 340B and why it matters. Date recorded: October 2, 2026